IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma.

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Activating mutations in isocitrate dehydrogenase 1/2 (IDH1/2) are observed across various cancers.
• The prognostic significance of IDH1/2 mutations in chondrosarcoma (CHS) remained uncharacterized.
• This study aimed to determine the prevalence and prognostic value of cancer-related gene mutations in CHS.

Purpose of the Study:

• To investigate the frequency of known cancer-associated gene mutations in chondrosarcoma.
• To evaluate the impact of these mutations, particularly IDH1/2, on patient overall survival (OS).
• To identify potential novel therapeutic targets in CHS.

Main Methods:

• DNA was extracted from formalin-fixed paraffin-embedded (FFPE) samples of 80 CHS patients.
• Next-generation sequencing was performed using the Ion AmpliSeq Cancer Hotspot Panel v2.
• Analysis focused on identifying single nucleotide variants and their correlation with clinical features and OS.

Main Results:

• Histological grade was the only clinical feature impacting OS.
• Activating IDH1/2 mutations were identified in 34% of patients (17% IDH1 R132, 13% IDH2 R172, 4% IDH2 R140).
• Patients with IDH1/2 mutations exhibited significantly lower OS (64%) compared to those without (93%; p<0.001).

Conclusions:

• IDH1/2 mutation status and histological grade are significant prognostic indicators for OS in CHS.
• The novel R140 IDH2 mutation identified may represent a potential therapeutic target for CHS treatment.
• Further research into IDH1/2 mutations could refine CHS patient management.